This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by van Rodijnen, W. F Articles by ter Wee, P. M Search for Related Content PubMed Articles by van Rodijnen, W. F Articles by ter Wee, P. M Social Bookmarking                         What's this?

Comparison of the AT1-receptor blockers candesartan, irbesartan and losartan for inhibiting renal microvascular constriction

Laboratory for Physiology, Vrije Universitet, w.van_rodijnen. physiol{at}med.vu.nl

Ton A van Lambalgen

Laboratory for Physiology, Vrije Universitet

Marco E van Teijlingen

Laboratory for Physiology, Vrije Universitet

Geert-Jan Tangelder

Laboratory for Physiology, Vrije Universitet

Piet M ter Wee

Department of Nephrology, Institute for Cardiovascular Research (ICaR-VU), Vrije Universiteit, Amsterdam, The Netherlands

Angiotensin II (Ang II) type 1 (AT₁) receptor blockers differ in their affinity for the AT₁-receptor, suggesting a dissimilar potency for inhibiting Ang II-induced vascular constriction. In the present study, we compared the effects of candesartan, irbesartan and losartan on the renal microvascular constriction to locally-formed Ang II, using isolated, perfused hydronephrotic rat kidneys. Addition of 1 nmol/L angiotensin I (Ang I, the precursor of Ang II) significantly reduced the diameters of interlobular arteries (ILAs; -47.6±2.6%), afferent arterioles (AAs; -43.6±2.3%) and efferent arterioles (EAs; -31.6±2.4%). Candesartan and irbesartan were more potent in antagonising the constriction to Ang I than losartan. By contrast, candesartan and irbesartan differed only slightly in potency. After a washing period of 60 minutes with drug-free medium, a second application of Ang I failed to induce vasoconstriction only in candesartan-treated kidneys. Pretreatment of hydronephrotic kidneys with candesartan, to further explore its antagonistic properties, shifted the dose-response curves of Ang II approximately 2 log units to the right without reducing the maximal Ang II-induced constriction of ILAs, AAs or EAs. Additionally, dose-response curves of Ang II were similar after short (10 minutes) and prolonged (60 minutes) preincubation with candesartan. Our findings indicate that candesartan and irbesartan are more potent inhibitors of renal microvascular constriction to locally-formed Ang II than losartan. The inhibitory effect of candesartan is more prolonged, suggesting a slow dissociation from the AT₁-receptor. Additionally, candesartan was found to block the Ang II-induced constriction of renal microvessels in a surmountable manner.

Key Words: isolated perfused hydronephrotic rat kidney • renal microvessels • AT1 antagonists • candesartan • irbesartan • losartan

References

• Israili ZH Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14 Suppl 1:S73-S86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Timmermans PB Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999;15:26F-8F.[Medline] [Order article via Infotrieve]
• Noda M., Shibouta Y., Inada Y. et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993;46:311-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cazaubon C., Gougat J., Bousquet F. et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-34.[Abstract/Free Full Text]
• Vanderheyden PML, Fierens FLP, De Backer JP, Fraeyman N., Vauquelin G. Distinction between surmountable and insurmountable selective AT(1) receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT(1) receptors. Br J Pharmacol 1999;126:1057-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Loutzenhiser R., Epstein M., Hayashi K., Takenaka T., Forster H. Characterization of the renal microvascular effect of angiotensin II antagonist, Dup 753: studies in isolated perfused hydronephrotic kidneys. Am J Hypertens 1991;4:309S-14S.[Medline] [Order article via Infotrieve]
• Morsing P.,Adler G., Brandt-Eliasson U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertens 1999;33:1406-13.[Abstract/Free Full Text]
• Ojima M., Inada Y., Shibouta Y., Wada T., Sanada T., Kubo K., Nishikawa K. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997;319:137-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Shibouta Y., Inada Y., Ojima M. et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993;266:114-20.[Abstract/Free Full Text]
• Navar LG, Imig JD, Zou LX, Wang CT Intrarenal production of angiotensin II. Seminars in Nephrology 1997;17:412-22.[Web of Science][Medline] [Order article via Infotrieve]
• ter Wee PM, Forster H., Epstein M. Video-microscopic assessment the role of tissue angiotensin-converting enzyme in the control of renal microcirculation. J Pharmacol Exp Ther 1997;281:434-9.[Abstract/Free Full Text]
• Loutzenhiser R., Hayashi K., Epstein M. Atrial Natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney. J Pharmacol Exp Ther 1988;246:522-8.[Abstract/Free Full Text]
• Steinhausen M., Snoei H., Parekh N., Baker R., Johnson PC Hydronephrosis: A new method to visualize vas afferens, efferens and glomerular network. Kidney Int 1983;23:794-806.[Web of Science][Medline] [Order article via Infotrieve]
• Loutzenhiser R.In situ studies of renal arteriolar function using the in vitro-perfused hydronephrotic rat kidney. Int Rev Exp Path 1996;36:145-60.[Medline] [Order article via Infotrieve]
• Kaplan NM Angiotensin II receptor antagonists in the treatment of hypertension. Am Fam Physician 1999;60:1185-90.[Web of Science][Medline] [Order article via Infotrieve]
• Ichikawa I., Harris PJ Angiotensin actions in the kidney: renewed insight into an old hormone. Kidney Int 1991;40:583-96.[Web of Science][Medline] [Order article via Infotrieve]
• Fabiani ME, Dinh DT, Nassis L., Casley DJ, Johnston CI In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan. Am J Hypertens 2000;13:1005-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Delacretaz E., Nussberger J., Biollaz J., Waeber B., Brunner HR Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertens 1995;25:14-21.[Abstract/Free Full Text]
• Heuer HJ, Schondorfer G., Hogemann AM Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997;11 Suppl 2:S55-S56.[Web of Science][Medline] [Order article via Infotrieve]
• Burnier M., Brunner HR Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 1999;10:S278-S282.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zhang JS, Van Meel JC, Pfaffendorf M., van Zwieten PA Different types of angiotensin II receptor antagonism induced by BIBS 222 in the rat portal vein and rabbit aorta; the influence of receptor reserve. J Pharmacol Exp Ther 1994;269:509-14.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 1 suppl, S204-S210 (2001)
DOI: 10.1177/14703203010020013601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by van Rodijnen, W. F Articles by ter Wee, P. M Search for Related Content PubMed Articles by van Rodijnen, W. F Articles by ter Wee, P. M Social Bookmarking                         What's this?